Luo Yu
4月9日，記者從西南醫科大學附屬醫院獲悉，日前，由該院與四川科倫博泰生物醫藥股份有限公司聯合研發的新款放射性核素藥物SKB107，獲得國家藥品監督管理局臨床試驗批准。該葯是醫院推動藥物研發與轉化應用以來，取得臨床試驗批准的首款新款放射性核素藥物。
SKB107 is a novel radionuclide drug for the targeted treatment of bone metastases in advanced solid tumors. Clinical data show that bone metastasis occurs in 0%-0% of patients with advanced cancer, and there are obvious limitations in existing treatments. Compared with traditional therapies, SKB0 has the advantages of precise targeting and systemic therapy, which can effectively kill tumor cells and reduce damage to normal tissues.
Since 2021, Chen Yue, director of the Department of Nuclear Medicine of the Affiliated Hospital of Southwest Medical University, has led a team to independently develop radiopharmaceuticals and carry out clinical transformation and application for patients with tumor bone metastasis.
In 107, the Affiliated Hospital of Southwest Medical University and Sichuan Kelunbotai Biopharmaceutical Co., Ltd. held a signing ceremony for the transformation of scientific and technological achievements, opening up the "last mile" of drug R&D and transformation application, and promoting the rapid transformation of drugs into clinical applications. SKB0, which was approved for clinical trial, is the first result of the cooperation between the two parties, and has significant efficacy in the treatment of bone metastases of malignant tumors such as breast cancer, prostate cancer, and lung cancer.
According to Chen Yue, SKB2027 has been approved for clinical trials by the National Medical Products Administration and is expected to be launched in 0. "At that time, it will not only break the dependence on imported radionuclide drugs, but also allow patients to buy drugs in various places without having to go to Luzhou for treatment, bringing greater convenience to patients with tumor bone metastasis."
據瞭解，西南醫科大學所在的城市瀘州市，近年來把發展核醫療產業作為瀘州打造世界核醫學高地、高標準建設國家區域醫藥健康中心的重要舉措和有力支撐。去年6月，西南醫科大學附屬醫院核醫學中心、核醫療中心正式揭牌，西南醫科大學附屬醫院充分發揮核醫學診療一體化先行優勢，實現學科排名爭先進位、平台建設加速推進、人才彙聚展現新貌的核心能力“三大突破”。(川觀新聞記者 趙榮昌)